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Cytokeratin 19 (CK19) is a specific cytoskeletal structure for simple epithelia, including bronchial and alveolar
epithelial cells (BAEC). Since CK19 is abundant in alveolar epithelial cells, and could be released from injured
alveolar epithelium in idiopathic pulmonary fibrosis (IPF), we investigated the levels of CK19 fragments in the
bronchoalveolar lavage fluids (BALF) of 16 patients with idiopathic pulmonary fibrosis (IPF) and 12 patients with
sarcoidosis using enzyme-linked immunoassay. There were also 19 control subjects (10 asymptomatic smokers and
nine non-smokers). BALF from the non-smokers as well as the asymptomatic smokers contained few CK19
fragments (02+02, 13+05 pg ml71 respectively). There were significantly high levels of CK19 in the BALF from
patients with IPF (73+14 pg/ml; P5001 vs. control non-smoker). Even if the levels of CK19 were expressed as
relative to the albumin concentration, significantly increased levels of CK19 fragments were noted in BALF from
patients with IPF. However, these levels were not found in BALF from patients with sarcoidosis. Importantly,
levels of CK19 fragment in BALF were significantly correlated to the number of neutrophils (r= 0791, P50001)
and eosinophils (r= 0771, P50001) but not to that of macrophages or lymphocytes in BALF from IPF patients.
Our results suggest the usefulness of CK19 measurement in BALF for assessing the presence of bronchiolo-alveolar
epithelial injuries in idiopathic pulmonary fibrosis.
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Idiopathic pulmonary fibrosis (IPF) is a chronic and
progressive lung disease of unknown aetiology with a poor
prognosis (1–4). Morphologically, IPF is characterized by
damage to the normal alveolar epithelium, including
cytoplasmic swelling, degeneration, hyperproliferation of
type II cells, necrosis and apoptosis (1,2,4,5). These various
degrees of chronic alveolar epithelial injury (alveolitis)
result in intra-alveolar and/or interstitial fibrosis. Many
studies of interstitial lung diseases have focused on
inflammatory cells and derived inflammatory mediators as
a cause of the damage to the alveolar epithelium. Analysis
of bronchoalveolar lavage fluid (BALF) obtained fromReceived 21 April 1999 and accepted in revised form 1 October
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tion, demonstrated by the increased numbers of inflamma-
tory cells in the alveoli (2–4,6). However, few studies of
specific markers on alveolar epithelial injuries have been
reported.
Cytokeratins are one of the most highly organized
cytoskeletal structures specifically expressed in vertebrate
epithelia (7,8). More than 25 subtypes of cytokeratins are
known to date and are expressed dierently in several types
of epithelia. In many studies, cytokeratins are used as a
specific marker for the dierentiation and classification of
the epithelium and derived cancer cells (7–10). Recently,
several types of cytokeratins were reported to be expressed
in normal subjects and regenerating respiratory epithelium
in patients with IPF (11). Cytokeratin 19 was found to be
abundant in a various types of respiratory epithelial cells
(11). Although precise mechanisms are unknown, frag-
ments of cytokeratin 19 (CK19) are soluble in serum and
can be detected with the aid of monoclonal antibodies in
patients with lung cancer (12,13). In the previous study, we
have demonstrated that increased levels of CK19 in
bronchoalveolar lavage fluid (BALF) from patients with
chronic inflammatory airway diseases was a useful marker# 2000 HARCOURT PUBLISHERS LTD
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background we measured the levels of CK19 fragment in
the BALF as a marker for alveolar epithelial injury in IPF.
Materials and methods
SUBJECTS
Sixteen untreated patients with IPF were entered into the
study (Table 1). The diagnosis of patients with IPF was
based on the following criteria: no clinical history of
exposure to environmental agents known to cause inter-
stitial lung disease, no history of chronic lung infection or
left ventricular failure, evidence of interstitial infiltrates on
chest roentogenogram and lung physiological function
consistent with a restrictive ventilatory defect including
decreased lung volumes, normal flow rates and decreased
single breath carbon monoxide diusing capacity (DLCO),
radiological findings using high-resolution computed tomo-
graphy scans; and/or transbronchial lung biopsy evidence
of interstitial pneumonia with varying degree of interstitial
fibrosis without evidence of granulomas, vasculitis, or
inorganic material visualized by light microscopy (1–4).
All patients with IPF had transbronchial lung biopsy, but
none had open lung biopsies. Furthermore, the cultures of
bronchial aspirate were negative for bacteria, mycobacteria
and fungi.
The diagnosis was established in 12 patients with
sarcoidosis (Table 1) by clinical features, appearance on
chest radiographs and lung biopsy as described previously
(15). Two patients with sarcoidosis were current tobacco
smokers and none of the patients had received corticoster-
oid therapy. Of the patients with sarcoidosis, five had
radiographic Stage I disease, five had Stage II disease and
two had Stage III disease.
Nineteen controlled subjects included nine non-smokers
and 10 asymptomatic smokers (Table 1). They had no
history of pulmonary disease. Fiberoptic bronchoscopy was
carried out to exclude the presence of bronchial lesions.
They had no sign of bronchial lesions and all had normal
chest roentgenogram.
All subjects underwent clinical, haematological and
chemical examinations in order to exclude the concomi-
tance of acute infection, chronic hepatitis and renal failure.
Forced vital capacity (FVC), forced expiratory volume inTABLE 1. Characteristics of subjects
n age (M/F) n'
Non-smokers 9 528+45 (4/5) 9
Smokers 10 516+38 (10/0) 10
IPF 16 671+17 (9/7) 16
Sarcoidosis 12 348+39 (6/6) 5
Data are shown as mean+SEM.
n: number of subjects who were entered in this study; n': number o
**P5001 compared with non-smokers; n.d.: not done.1 sec (FEV1), and DLCO were measured in 40 out of 48
subjects (Table 1). Informed consent was obtained from all
subjects.
BRONCHOALVEOLAR LAVAGE
All subjects were premedicated 30 min before fiberoptic
bronchoscopy with atropine sulphate (05 mg intramuscu-
larly) and topical lidocaine anesthesia. The bronchoscope
was wedged into the middle lobe bronchus and three
aliquots of sterile saline solution were instilled to a total
volume of 150 ml and aspirated immediately. Cell viability
was assessed by a trypan blue dye exclusion test and the
total cell concentration was determined by counting in a
Burker chamber. Cytological preparations were made by
cytocentrifugation (Cytospin 2; Shandon, Pittsburgh, PA,
U.S.A.), stained with modified May-Giemsa stain (Di
Quick; American scientific Products, McGaw Park, IL,
U.S.A.), and dierential counts were performed by count-
ing 200 cells per sample. Cells were isolated from BALF by
centrifugation at 200g for 10 min and BALF was stored at
770 C until evaluation.
BIOCHEMICAL ANALYSIS OF
BRONCHOALVEOLAR LAVAGE FLUIDS
Fragments of CK19 in BALFs were measured by a two-
step sandwich immunoassay using the streptavidin-biotin
technology (Enzymun-Test CYFRA 21-1; Boehringer
Mannheim GmbH, Tutzing, FRG) (12–14). In parallel
studies, the albumin concentration in BALFs was deter-
mined by ELISA (Albuwell; Exocell Inc., Philadelphia, PA,
U.S.A.).
STATISTICAL ANALYSIS
Results are reported as mean+standard error of the mean.
The data from each subject were first compared using
Kruskal–Wallis non-parametric one-way analysis of var-
iance. When significant, the dierences between the groups
were further compared using nonparametric Mann–Whit-
ney U-tests and the Bonferroni test with an adjustment of
the P values (P5005). Correlations were tested by%VC FEV1 % %DLCO
1055+170 793+35 n.d.
1056+49 784+34 n.d.
684+56** 812+34 407+67
1104+75 838+62 1010+247
f subjects who were examined with pulmonary function test;
CYTOKERATIN 19 IN BRONCHOALVEOLAR LAVAGE FLUID 157calculating the Spearman correlation coecient r. A P
value 5005 was considered significant.
Results
LUNG FUNCTION
To confirm pulmonary disease in patients with IPF, we
examined lung function data from each group (Table 1).
Our control subjects, including non-smokers and asympto-
matic smokers, showed both normal %VC and FEV1%. In
contrast, patients with IPF had significantly decreased
%VC and %DLCO. No abnormality of the percent vital
capacity nor %DLCO was shown in five sarcoidosis
patients.
CELLULAR ANALYSES OF
BRONCHOALVEOLAR LAVAGE FLUIDS
As shown in Table 2, asymptomatic smokers tended to have
higher levels of total cell and macrophages numbered
compared to the controlled non-smokers. Total cell
concentration of BALF from patients with IPF was
significantly higher than that from the control non-smokers
(P5001). The significant increase in neutrophils and
eosinophils was also noted in BALF from patients with
IPF (P5001). In sarcoidosis patients, total cells in BALF
tended to be increased, and lymphocytes were significantly
elevated (P5005).
CYTOKERATIN 19 FRAGMENTS IN
BRONCHOALVEOLAR LAVAGE FLUIDS
Cytokeratin 19 in BALF was significantly elevated in
patients with IPF compared to the controlled non-smokers
and the asymptomatic smokers (Fig. 1). A correction of
CK19 content for the albumin concentrate still showed
significantly elevated levels in BALF of patients with IPF
(Fig. 2). CK19 fragments levels in BALF from patients with
sarcoidosis were significantly increased as those from non-
smokers (P5005). However, CK19 relative to albumin
concentrations in BALF from patients with sarcoidosis
were not significantly dierent from those from nonsmok-
ing control subjects.TABLE 2. Cell concentrations (6104/ml) in bronchoalveolar lava
n Total cells Macrophages
Non-smokers 9 164+41 147+40
Smokers 10 263+41 237+41
IIP 16 405+77* 251+48
Sarcoidosis 12 272+37 183+36
Data are shown as mean+SEM;
**P5001 compared with non-smokers; *P5005 compared wiImportantly, a significant correlation coecient to CK19
levels was noted both in neutrophil and eosinophil numbers
in BALF from patients with IPF (Table3). There were no
correlations between CK19 levels and other cell types in
BALF.
Discussion
In the present study, we demonstrated that cytokeratin 19
(CK19) fragments are elevated in the epithelial lining fluid
obtained by BAL from patients with idiopathic pulmonary
fibrosis (IPF). These levels were not found in BALF of
control non-smokers or asymptomatic smokers, nor in
patients with sarcoidosis. In addition, we showed that
CK19 levels correlated with both neutrophil and eosinophil
numbers in BALF from patients with IPF, suggesting that
levels of CK19 fragments in BALF may reflect the severity
of alveolitis and damages of respiratory epithelium in
patients with IPF.
MECHANISM AND SIGNIFICANCE OF
INCREASED CK19 LEVELS IN BALF FROM
IPF PATIENTS
Since Cytokeratin 19 is a cytoskeletal structure expressed
only in respiratory epithelial cells in lungs, detection of
CK19 in epithelial lining fluid in IPF patients might reveal
possible pathological changes relating to the alveolar
epithelial injuries as following.
As a result of alveolar epithelial injury attacked by
activated neutrophils and eosinophils (2–4,6,16–21), CK19
fragments would be released from the cytoplasm of
damaged alveolar epithelium. On this point, we have
previously reported that neutrophil elastase can induce
CK19 fragments release from bronchial epithelial cells (14).
Activated neutrophils and eosinophils would release
various injurious proteinases and oxidants which might
have CK19 released from epithelial cells. However, what
kind of injurious mediators could be involved in IPF lungs
remains to be explained. The critical roles of chronic
neutrophil and eosinophil accumulation in the air space,
leading to persistent injury of the epithelial barrier with
abnormal repair, has been advocated in the genesis of
interstitial and intra-alveolar fibrosis (2–4,6,22). Sincege fluid
Lymphocytes Neutrophils Eosinophils
16+04 03+02 0+0
22+06 03+01 01+01
115+64 64+40** 25+19**
86+17** 02+01 01+00
th non-smokers.
FIG. 1. Shown are cytokeratin 19 concentrations measured
by ELISA in bronchoalveolar lavage fluids obtained from
control non-smokers, asymptomatic smokers, patients
with idiopathic pulmonary fibrosis (IPF) and patients
with sarcoidosis. Each bar represents the
median+interquartile range from each group. *:
smoker; *: non-smoker.
FIG. 2. Shown are levels of cytokeratin 19 fragments
relative to albumin concentrations in bronchoalveolar
lavage fluids from control non-smokers, asymptomatic
smokers, patients with idiopathic pulmonary fibrosis
(IPF) and patients with sarcoidosis. Levels of cytokeratin
19 and albumin were examined by ELISA as described in
Materials and Methods. Each bar represents the
median+interquartile range from each group.
TABLE 3. Correlation between concentrations of cytokeratin
19 fragments and cellular profiles in bronchoalveolar lavage
fluid (BALF) of idiopathic pulmonary fibrosis
Cytokeratin 19 n r P
BALF total cells 16 0388 01560
BALF neutrophils 16 0791 00002
BALF eosinophils 16 0771 00004
BALF lymphocytes 16 70090 07551
BALF macrophages 16 0428 01135
158 M. INAGE ET AL.excess neutrophils and eosinophils in BAL fluid have been
associated with a higher likelihood of disease pro-
gression and a failure to respond to immunosuppressi
on among patients with IPF (2–4,6,16–21), increased levels
of CK19 fragments correlated to neutrophils and eosino-
phils might be one of the prognostic factors for patients
with IPF. Further studies will be needed to clarify these
points, and chronological evaluation of CK19 levels
in BALF may be helpful to predict the development of
fibro-tic lesions in IPF.
Although the dominant pathological abnormalities are
localized in the alveoli, small airways are also involved in
the disease process of IPF (23). In addition, patients with
IPF who showed increased sputum production have been
reported to have a poor prognosis (24), suggesting the
involvement of airways in IPF. Our previous in vitro study
confirmed that CK19 fragments are released from bronchial
epithelial cells, but not alveolar macrophages, neutrophils
or fibroblasts (14).Thus since CK19 is a cytoskeletal
structure specific in all types of respiratory epithelial cells,
increased levels of CK19 fragments in BALF may be
derived not only from alveolar epithelial cells but also from
bronchial epithelial cells in patients with IPF.
In IPF lungs, If the damage includes the proximal
portion of the acini and the terminal bronchioles, epithelial
renewal also includes bronchial epithelial cells with
cuboidal cells, clara cells and, occasionally, ciliated cells
(4–6,11). In some areas, the regenerating epithelial cells
stack upon one another and show evidence of squamous
metaplasia (1–6,11). In the context that all these kinds of
epithelial cells in IPF lungs have been reported to contain
CK19 abundantly in their cytoplasm (11), and proliferating
lung cancer cells secrete CK19 into culture supernatant in
vitro (25), proliferating and regenerating alveolar epithelial
cells in IPF lungs may actively secrete CK19 fragments.
Although there is a tendency to increase CK19 fragments
in BALF from patients with sarcoidosis, CK19 levels
relative to albumin concentrations in BALF were not
significantly dierent from those of control subjects. These
data may relate to the pathology of sarcoidosis lungs, in
which damage to and activation of pulmonary epithelia are
thought to be rare and weak (15,26–28). The data that
BALF from sarcoidosis patients contained neither much
CK19 fragments nor neutrophils and eosinophils may
further supports this hypothesis.
CYTOKERATIN 19 IN BRONCHOALVEOLAR LAVAGE FLUID 159A COMPARISON WITH OTHER MARKERS
FOR DAMAGES IN EPITHELIAL CELLS IN
IPF
Besides cytokeratin 19, several possible markers for
assessing the alveolar epithelial injuries has been proposed.
These include surfactant protein A (SP-A) (29), surfactant
protein D (30), KL-6 (31) and alkaline phosphatase (ALP)
(32) in BALF. The significance of the increased levels of
CK19 would be dierent from these for the following
reasons: Firstly, expression of SP-A and KL-6 are limited in
normal type II alveolar epithelial cells. In contrast, CK19 is
widely expressed not only in normal type II epithelial cells
but also any other epithelium of the respiratory tract
including proliferating and metaplastic alveolar epithelial
cells (11). Thus CK19 levels may reflect the ‘total epithelial
injuries’ of the lungs. ALP is expressed not only in epithelial
cells but also in non-epithelial cells in the lungs (32).
Secondly, KL-6 is a surface carbohydrate antigen expressed
only on the cell surface of type II alveolar epithelial cells. In
contrast, CK19 is a cytoskeletal structure existed in the
cytoplasm of respiratory epithelium. The release mechan-
ism of CK19 would be dierent from that of KL-6,
implicating the dierent pathological significances. Finally,
SP-A and SP-D are proteins secreted from normal type II
alveolar epithelial cells. SP-A levels in BALF from patients
with IPF were significantly decreased as results of the
dysfunction or hypofunction of the damaged alveolar type
II cells (29). SP-D in BALF from patients with IPF has
been reported to be the same level as those from control
subjects (30). The fact that levels of both SP-A and SP-D in
BALF were not parallel to the level of CK19 in BALF in
patients with IPF, suggest that levels of CK19 may
implicate a unique aspect of the pathological changes in
IPF.
We concluded that levels of CK19 fragments in BALF
would reflect bronchioloalveolar epithelial injuries, relating
to the severity of neutrophil and eosinophil alveolitis in
patients with IPF. This simple marker could be included in
studies to evaluate the staging, severity, follow-up and
ecacy of the therapy in idiopathic pulmonary fibrosis.
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